logo
India's Milky Mist files draft papers for $236 million IPO

India's Milky Mist files draft papers for $236 million IPO

Reuters4 days ago
July 21 (Reuters) - Milky Mist has filed for a 20.35 billion rupees ($235.94 million) initial public offering, comprising a fresh issue of shares up to 17.85 billion rupees and existing offer-for-sale of 2.5 billion rupees, draft papers showed on Monday.
($1 = 86.2490 Indian rupees)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HCA raises annual profit forecast on resilient demand for medical care
HCA raises annual profit forecast on resilient demand for medical care

Reuters

time10 minutes ago

  • Reuters

HCA raises annual profit forecast on resilient demand for medical care

July 25 (Reuters) - HCA Healthcare (HCA.N), opens new tab raised its 2025 profit forecast on Friday as it expects sustained demand for medical procedures to cushion a hit from U.S. President Donald Trump's potential tariffs. Health insurers have flagged higher-than-anticipated costs in its individual plans that come under the Affordable Care Act, also known as Obamacare, and its Medicaid plans for low-income people. Analysts have said they expect this trend to benefit hospital operators, but warned that proposed federal budget cuts could hit their earnings. HCA earned second-quarter adjusted profit of $6.84 per share, beating analysts' estimates of $6.25 per share, according to data compiled by LSEG. The company expects 2025 profit to be about $25.50 to $27 per share, compared with its previous forecast of $24.05 to $25.85 per share.

Google partners with Italy's Energy Dome on zero-emission power supply
Google partners with Italy's Energy Dome on zero-emission power supply

Reuters

time39 minutes ago

  • Reuters

Google partners with Italy's Energy Dome on zero-emission power supply

MILAN, July 25 (Reuters) - Italian energy storage firm Energy Dome said on Friday it had entered a commercial partnership with Google (GOOGL.O), opens new tab to supply carbon-free energy to the grids that power the operations of the U.S. tech giant. As part of the agreement, Google has made a strategic investment in Milan-based Energy Dome, which has developed a CO2 battery technology to support the energy transition through long-duration energy storage solutions, the companies said in a joint statement. They did not disclose the financial details. Google joins other investors in the Italian energy storage firm such as Oman's sovereign wealth fund and global tank storage operator Vopak ( opens new tab. Google's first commercial long-duration energy storage deal is part of a growing number of advanced energy technologies the group needs to hit a goal to run its operations on 24/7 carbon-free energy by 2030. Energy Dome's CO2-based system stores energy by compressing and liquefying carbon dioxide, which is later expanded to generate electricity. The technology avoids the use of scarce raw materials such as lithium and copper, making it potentially attractive to European policymakers seeking to reduce reliance on critical minerals and bolster energy security. Energy Dome launched its first commercial-scale plant in Sardinia in 2022 with a view to completing it by the end of 2024, with a 24-hour cycle and a 20-megawatt capacity able to power 13,000-15,000 houses.

EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy
EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy

Reuters

time39 minutes ago

  • Reuters

EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy

July 25 (Reuters) - Europe's medicines regulator did not recommend the approval of Sarepta Therapeutics' (SRPT.O), opens new tab gene therapy Elevidys for a type of rare muscular dystrophy, the health agency said on Friday. Shares of the company were down nearly 17% at $10.70 in premarket trading. The EU committee's negative opinion comes as yet another setback for the company that is facing increasing regulatory scrutiny after two recent deaths of patients who received Elevidys. Sarepta and its partner outside the U.S., Roche (ROG.S), opens new tab, did not immediately respond to Reuters' requests for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store